Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
17 10월 2023 - 5:05AM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced that it will host a live webcast at 8:00 a.m. ET / 2:00
p.m. CEST on Monday, October 23, 2023 to review interim monotherapy
data from its Phase 1/2 clinical trial evaluating HPN328 in small
cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)
presented at the European Society of Medical Oncology Congress
(ESMO) 2023.
During the call, management will provide an in-depth review of
the HPN328 interim data presented that day at ESMO Congress 2023.
Harpoon will present data from over 70 patients across multiple
DLL3 expressing tumor types in HPN328 monotherapy cohorts, with an
emphasis on the ongoing 1 mg priming cohorts with target doses up
to 24 mg. Full enrollment of these 1 mg priming dose cohorts will
be the basis for selecting the recommended Phase 2 dose(s) by the
end of this year. The ESMO poster will share tolerability data from
all enrolled patients and preliminary response data in patients at
doses above the efficacious threshold of 1.215 mg. For more on the
ESMO abstract, please see the October 9, 2023 press release.
Registration InformationThe live webcast will
take place on Monday, October 23, 2023, from 8:00 a.m. to 9:00 a.m.
ET / 2:00 p.m. to 3:00 p.m. CEST. To register for the event, please
click here. A replay of the webcast will be available shortly after
the live event and can be accessed at the same weblink.
Details of the ESMO poster presentation are as follows:
Abstract Title: Interim Results from a Phase
1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended
DLL3-targeting T-Cell Engager in Patients (pts) with Small Cell
Lung Cancer (SCLC) and other Neuroendocrine Neoplasms
(NEN)Presentation Number: 698PSession
Number/Title: Developmental TherapeuticsSession
Date, Time: Monday, October 23, 2023, 12:00 – 13:00
CESTPresenter: Noura Choudhury,
M.D.Location: Hall 8
About HPN328HPN328 targets delta-like canonical
Notch ligand 3 (DLL3) and is based on Harpoon’s proprietary
Tri-specific T cell Activating Construct (TriTAC®) platform
designed to recruit a patient’s own immune cells to kill tumor
cells. HPN328 is being evaluated as monotherapy in an ongoing
open-label, multicenter two-part study to assess the safety,
tolerability, and pharmacokinetics in patients with advanced
cancers associated with expression of DLL3.
In March 2022, the U.S. Food and Drug Administration (FDA)
granted Orphan Drug Designation to HPN328 for the treatment of
small cell lung cancer (SCLC).
About Harpoon Therapeutics Harpoon
Therapeutics is a clinical-stage immunotherapy company
developing a novel class of T cell engagers that harness the power
of the body’s immune system to treat patients suffering from cancer
and other diseases. T cell engagers are engineered proteins that
direct a patient’s own T cells to kill target cells that express
specific proteins, or antigens, carried by the target cells. Using
its proprietary Tri-specific T cell Activating Construct (TriTAC®)
platform, Harpoon is developing a pipeline of novel
TriTACs initially focused on the treatment of solid tumors and
hematologic malignancies. Harpoon has also developed a proprietary
ProTriTAC™ platform, which applies a prodrug concept to its
TriTAC platform to create a therapeutic T cell engager that
remains inactive until it reaches the tumor. Harpoon’s third
proprietary technology platform, extended release TriTAC-XR, is
designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“expect,” “will,” and similar expressions (as well as other words
or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Harpoon Therapeutics’
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties that could cause Harpoon Therapeutics’ clinical
development programs, future results, or performance to differ
significantly from those expressed or implied by the
forward-looking statements. Forward-looking statements contained in
this press release include but are not limited to, statements about
the expected timing, progress, and results of Harpoon Therapeutics’
clinical trials, including interim results of clinical trials and
the safety and tolerability profile of product candidates, the
association of interim clinical data and preclinical results with
potential treatment outcomes and other statements that are not
historical fact. Many factors may cause differences between current
expectations and actual results, including unexpected safety or
efficacy data observed during clinical studies, preliminary data,
and trends may not be predictive of future data or
results, may not demonstrate safety or efficacy, or lead to
regulatory approval by the FDA or other regulatory agencies,
clinical trial site activation or enrollment rates that are lower
than expected, changes in expected or existing competition, changes
in the regulatory environment, the uncertainties and timing of the
regulatory approval process, the timing and results of unexpected
litigation or other disputes, and the sufficiency of Harpoon
Therapeutics’ cash resources. These and other factors that may
cause Harpoon Therapeutics’ actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Harpoon Therapeutics’ filings with
the U.S. Securities and Exchange Commission, including under
“Risk Factors” in Harpoon Therapeutics’ quarterly report on Form
10-Q for the quarter ended June 30, 2023, and future filings
by Harpoon Therapeutics. Except as required by
law, Harpoon Therapeutics assumes no obligation to update
any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes
available.
Contacts:Harpoon TherapeuticsAna
Kaporakapor@harpoontx.com
Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024